Roflumilast
- CAS No.
- 162401-32-3
- Chemical Name:
- Roflumilast
- Synonyms
- Daliresp;Daxas;BY 217;Roster;CS-1960;Roflost;BYK 20869;APTA 2217;B 9302-107;RofluMilas
- CBNumber:
- CB7412688
- Molecular Formula:
- C17H14Cl2F2N2O3
- Molecular Weight:
- 403.21
- MOL File:
- 162401-32-3.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/7/24 17:31:20
| Melting point | 158°C |
|---|---|
| Boiling point | 430.6±45.0 °C(Predicted) |
| Density | 1.471±0.06 g/cm3(Predicted) |
| storage temp. | -20°C |
| solubility | DMSO: soluble20mg/mL, clear |
| pka | 9.89±0.70(Predicted) |
| form | powder |
| color | white to beige |
| Merck | 14,8249 |
| Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
| InChI | InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24) |
| InChIKey | MNDBXUUTURYVHR-UHFFFAOYSA-N |
| SMILES | C(NC1C(Cl)=CN=CC=1Cl)(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 |
| CAS DataBase Reference | 162401-32-3(CAS DataBase Reference) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H315-H319-H335 | |||||||||
| Precautionary statements | P261-P264-P271-P280-P302+P352-P305+P351+P338 | |||||||||
| Hazard Codes | Xi | |||||||||
| Risk Statements | 36/37/38 | |||||||||
| Safety Statements | 26 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | CV3325600 | |||||||||
| HS Code | 2933.39.4100 | |||||||||
| NFPA 704 |
|
Roflumilast price More Price(4)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | SML1099 | Roflumilast ≥98% (HPLC) | 162401-32-3 | 10MG | ₹7079.55 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | SML1099 | Roflumilast ≥98% (HPLC) | 162401-32-3 | 50MG | ₹28740.38 | 2022-06-14 | Buy |
| TCI Chemicals (India) | R0193 | Roflumilast | 162401-32-3 | 250MG | ₹9700 | 2022-05-26 | Buy |
| TCI Chemicals (India) | R0193 | Roflumilast | 162401-32-3 | 1G | ₹19100 | 2022-05-26 | Buy |
Roflumilast Chemical Properties,Uses,Production
Description
Roflumilast is a selective, orally active PDE4 inhibitor thatwas approved
in Germany in July 2010 as an add-on to bronchodilator treatment for
maintenance therapy of severe chronic obstructive pulmonary disorder
(COPD) associated with chronic bronchitis in adult patients with a history
of frequent exacerbations .
Roflumilast and its primary metabolite roflumilast N-oxide are potent and
competitive inhibitors of PDE4 and are equipotent against PDE4A, B, andD
but inactive against PDE4C and the other ten members of the PDE family
(PDEs 1–3, 5–11). Despite its inhibition of PDE4D (IC50=0.80 nM, N-oxide
IC50=2.0 nM), roflumilast shows the lowest incidence of nausea (3–5%)
among the PDE4 inhibitors investigated in clinical trials.Anti-inflammatory
effects of roflumilast have been demonstrated in preclinical cellular and
animal models. Roflumilast is synthesized in four steps from
3-(cyclopropylmethoxy)-4-hydroxybenzaldehyde. The difluoromethyl
ether is introduced by alkylation of the free phenolic group with
chlorodifluoromethane and base. The aldehyde moiety is oxidized to the
benzoic acid, which is then converted to an acid chloride and coupled with
3,5-dichloro-4-aminopyridine.
Roflumilast is rapidly absorbed and metabolized to its active metabolite,
roflumilast N-oxide. Metabolism is mediated by CYP3A4
and CYP1A2.
Chemical Properties
Crystallin Solid
Uses
Roflumilast (Daxas) is a selective inhibitor of PDE4 with IC50 of 0.2-4.3 nM.
Definition
ChEBI: A benzamide obtained by formal condensation of the carboxy group of 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid with the amino group of 3,5-dichloropyridin-4-amine. Used for treatment of bronchial asthma and chronic obstructive pulmonary disease
Mechanism of action
Roflumilast is the more potent of the two drugs, and along with its active metabolite, roflumilast-N-oxide, it is nonselective in its inhibitory action on PDE4B and PDE4D. The PDE4B appears to be the most closely linked to anti-inflammatory effects, whereas the PDE4D receptor subtype is thought to be linked to nausea, possibly through a central effect. Roflumilast exhibits 80% oral bioavailability and has an elimination half-life of 10 hours, whereas the N-oxide has an elimination half-life of 20 hours and has shown no drug interactions. Clinical trials in patients with asthma or COPD are quite promising.
Pharmacokinetics
Roflumilast is well absorbed on oral administration and has a half-life of 10 hours. Roflumilast is metabolized in the liver to its N-oxide derivative, which also is a PDE4 inhibitor, and it has a plasma half-life of 20 hours.
Clinical Use
Roflumilast is currently undergoing clinical trials in Europe for use in the treatment of both asthma and COPD.
Roflumilast Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Micro Orgo Chem | +91-91-022-24969510 +91-9082984052 | Mumbai, India | 66 | 58 | Inquiry |
| Nivika Chemo Pharma Pvt Ltd | +91-9824176501 +91-9824176501 | Gujarat, India | 15 | 58 | Inquiry |
| Glenmark Pharmaceuticals Limited | +912240189999 | Maharashtra, India | 93 | 58 | Inquiry |
| Hetero Drugs Limited | +91-4023704923 +91-4023704923 | Telangana, India | 296 | 58 | Inquiry |
| Bioaltus Laboratories Pvt Ltd | +91-2249744539 +91-9820139885 | Maharashtra, India | 34 | 58 | Inquiry |
| Ralington Pharma | +91-7948911722 +91-9687771722 | Gujarat, India | 1350 | 58 | Inquiry |
| Navone Specialties (OPC) Pvt Ltd | +91-9323789882 +91-9323789882 | Maharashtra, India | 144 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |